retatrutide phase 2 study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks Lilly's triple agonist achieves 16.8%

[15] [16] Readers should refer to the current NICE technology appraisal and the emc SmPC for Mounjaro for the most up-to-date access criteria, as commissioning arrangements continue to evolve

When combined with lifestyle changes and medical support, GLP-1 injections can be a game-changer for those who have struggled with weight loss in the past

If you need appetite suppression and significant weight loss, a GLP-1 agonist like PlexusDx Semaglutide Injection is necessary

Readers should verify the current authorisation status via the MHRA and EMA medicines databases, as the regulatory position may change as Phase 3 data mature

Is it better than Tirzepatide